Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Jun;11(6):307.
doi: 10.1038/nrclinonc.2013.208-c2. Epub 2014 Apr 29.

Reply: Regulatory T cells-an important target for cancer immunotherapy

Charles G Drake  1 , Evan J Lipson  1 , Julie R Brahmer  1
Affiliations
Comment

Reply: Regulatory T cells-an important target for cancer immunotherapy

Charles G Drake et al. Nat Rev Clin Oncol. 2014 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Shin JI, Ha S-J. Regulatory T cells—an important target for cancer immunotherapy. Nat. Rev. Clin. Oncol. http://dx.doi:10.1038/nrclinonc.2013.208-c1. - DOI - PubMed
    1. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 2014;11:24–37. - PMC - PubMed
    1. Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013;210:1695–1710. - PMC - PubMed
    1. Selby MJ, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2013;1:32–42. - PubMed
    1. Korman AJ, et al. Role of the immunoglobulin constant region in the antitumor activity of antibodies to cytotoxic T-lymphocyte antigen-4 (CTLA-4) [abstract] J. Clin. Oncol. 2013;31(Suppl.):a9055.

MeSH terms

Substances